Reese Marketos played the role of government prosecutor in a False Claims Act case about alleged off-label use of an HIV drug ...

Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...

J&J’s comments and guidance update come as the company kicks off 2025’s first-quarter earnings round for large drugmakers.

For medical-technology and pharmaceuticals manufacturing, “the most effective answer is not tariffs but tax policy,” Johnson ...

Health system pharmacists and physicians are monitoring a wave of expected new drug approvals between late 2024 and third quarter of 2025. A recent article published in the American Journal of ...

President Trump unveiled a wide-ranging executive order that aims to lower drug prices, boost transparency into fees charged ...

The Trump administration is proceeding with probes into the national security implications of pharmaceutical imports.

The Dark Secrets of Johnson & Johnson.” Gardiner Harris, a former pharmaceutical reporter for The New York Times and a reporter for The Wall Street Journal, effectively explains the legal battles ...

Q1 adjusted EPS of $2.77 beat estimates; cancer drug Darzalex sales jumped 20.3% ... % or 4.2 operationally to $13.90 billion. Also Read: Johnson & Johnson, Protagonist Tout Positive Results ...

The chief executive of Johnson & Johnson has warned that potential ... Joe Wolk said the administration’s investigation into drug imports, widely seen as a first step toward imposing levies ...

(Reuters) -Johnson & Johnson Chief Executive Joaquin ... to mitigate supply chain vulnerabilities and prevent any drug shortages that can result from tariffs. J&J is the first major healthcare ...